This immunotoxin was achieved by conjugating/fusing the anti-HLA-A monoclonal antibody to α-sarcin. It was expressed in CHO and purified with affinity chromatography. The immunotoxin selectively binds to human bladder carcinoma cells. Once bind, alpha-Sarcin enters into the cells by receptor-mediated endocytosis and interacts with a single bond in the targeted ribosome and breaks it, causing the ribosome to be inactivated. It was designed for treatment of bladder carcinoma.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.